Synergistic activity of friedelan-3β-ol isolated from Euphorbia lactea and doxorubicin against MDA-MB-231 breast cancer cell line
Science, Engineering and Health Studies · 18.10.2022
DOI: 10.14456/sehs.2022.27 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, Engineering and Health Studies, erschienen am 18.10.2022. Verfasst von Supusson Pengnam und 4 weiteren Autor:innen.
Abstract (Originalsprache)
The cytotoxic activity of three triterpenoid compounds namely, friedelin [1], friedelan-3β-ol [2] and taraxerol [3] isolated from hexane fraction Euphorbia lactea Haw. was investigated in breast cancer cell lines MDA-MB-231 and MCF-7. Dose-dependent cytotoxic activity of these compounds was detected in MDA-MB-231 cells. Of the three compounds, [2] elicited the strongest inhibitory effect. The interplay between [2] and doxorubicin (Dox) in a series of combination treatments was analyzed in MDA-MB-231. Computer modeling software CompuSyn revealed that [2] and Dox exhibited a synergistic relationship over a broad range of concentration. The ratio of [2]:Dox at 25:1 µg/mL was predicted to achieve a 90% inhibitory effect with the lowest dose of each agent, thus allowing a dose reduction of [2] and Dox by ~30 and ~3 fold, respectively. Finally, the percentage of apoptotic cells in MDA-MB-231 treated with [2]:Dox at a 25:1 µg/mL combination was markedly higher than cells treated with 1x and 2x the concentration of each individual agent, supporting the predicted synergism. Together, the results highlighted [2] as an anticancer phytochemical exhibiting synergistic activity with Dox and warranted further research to assess the possibility to exploit this synergy for breast cancer treatment.
Schlagwörter
Zitieren
APA
Pengnam, S., Wongprayoon, P., Limpachayaporn, P., Rayanil, K., & Charoensuksai, P. (2022). Synergistic activity of friedelan-3β-ol isolated from Euphorbia lactea and doxorubicin against MDA-MB-231 breast cancer cell line. Science, Engineering and Health Studies. https://doi.org/10.14456/sehs.2022.27
Vancouver
Pengnam S, Wongprayoon P, Limpachayaporn P, Rayanil K, Charoensuksai P. Synergistic activity of friedelan-3β-ol isolated from Euphorbia lactea and doxorubicin against MDA-MB-231 breast cancer cell line. Science, Engineering and Health Studies. 2022. doi:10.14456/sehs.2022.27
BibTeX
@article{Pengnam2022,
author = {Pengnam, Supusson and Wongprayoon, Pawaris and Limpachayaporn, Panupun and Rayanil, Kanok‐on and Charoensuksai, Purin},
title = {Synergistic activity of friedelan-3β-ol isolated from Euphorbia lactea and doxorubicin against MDA-MB-231 breast cancer cell line},
journal = {Science, Engineering and Health Studies},
year = {2022},
doi = {10.14456/sehs.2022.27}
}
EUVIMED